Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial-Reference-Cited by-同舟云学术

Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial

Published:2014-02 Issue:2 Volume:26 Page:81-89
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Láng I.,Bell R.,Feng F.Y.,Lopez R.I.,Jassem J.,Semiglazov V.,Al-Sakaff N.,Heinzmann D.,Chang J.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference31 articles.

1. Global cancer facts and figures;American Cancer Society,2008

2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

4. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

5. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group;Marty;J Clin Oncol,2005

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer;Cancer Research and Treatment;2022-10-15

2. Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958);Breast Cancer Research and Treatment;2022-09-12

3. Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments;Cancers;2021-11-18

4. Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center;Pharmaceutics;2021-05-10

5. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study;ESMO Open;2021-04